A Study on the Efficacy and Safety of Telmisartan, Clopidogrelin and Leflunomide in patients with IgA nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000776

Enrollment

Unknown

Registered

2010-02-10

Start date

2010-02-27

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lgA nephropathy

Interventions

1:Telmisartan+ Clopidogrelin placebo + Leflunomide placebo

2:Telmisartan + Clopidogrelin+ Leflunomide placebo

3:Telmisartan + Clopidogrelin placebo + Leflunomide

4:Telmisartan + Clopidogrelin + Leflunomide

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Renal biopsy proven lgA nephropathy in 1 year, grade of Lee II-IV; 2. Age range 18-55 years, male and female; 3. BP<=130/80mmHg (with or without drug); 4. Proteinuria levels of 0.5 to 3.5g/24hr; 5. Scr<265.2umol/L(3mg/dl); 6. To sign informed consent.

Exclusion criteria

Exclusion criteria: 1. History of hypersensitivity to experiment medicine; 2. BP10*10^9/L; 5. secondary lgA nephropathy; 6. steroids and immunosuppressive drugs treatment during previous 3 months.

Design outcomes

Primary

Measure	Time frame
Urine Protein;	—

Secondary

Measure	Time frame
Renal function, eGFR, plasma-albumin;	—

Countries

China

Contacts

Public ContactXiangmei Chen

xmchen301@126.com+86 010 66935462

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026